Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-01-03 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司第二届监事会2025年第一次临时会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a resolution passed at the Supervisory Board's first extraordinary meeting in 2025. It details the meeting's convening, attendance, and the approval of a proposal regarding related party transactions for 2024 and 2025. It references compliance with company law and articles of association, and notes that the proposal will be submitted to the shareholders' meeting for approval. The document is short (833 characters) and serves as an official announcement of a board/management decision rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a shareholder vote result or a regulatory filing of another type. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2025-01-03 Chinese
圣湘生物科技股份有限公司2023年第二期限制性股票激励计划预留授予激励对象名单
Remuneration Information Classification · 95% confidence The document is a list of reserved grant recipients for a restricted stock incentive plan for 2023, including names, positions, and stock quantities. It is issued by the company's board and dated December 16, 2024. The content focuses on stock incentive allocations to management and key personnel, which is related to remuneration and compensation information. There is no indication of a full annual report, audit report, or financial statements. The document is not a meeting presentation, voting result, or regulatory filing. It specifically details stock incentives granted to executives and employees, fitting the definition of Remuneration Information (DEF 14A). The document length is short and focused on compensation details, confirming this classification.
2024-12-16 Chinese
圣湘生物科技股份有限公司关于向2023年第二期限制性股票激励计划激励对象授予预留部分限制性股票的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the granting of reserved restricted shares under the company's 2023 second phase restricted stock incentive plan. It includes specifics about the number of shares, grant date, pricing, eligibility, approval procedures, legal opinions, and financial impact estimates. The content focuses on the stock incentive plan and its implementation rather than financial results, management changes, or shareholder voting outcomes. It is not a full financial report, earnings release, or proxy statement. The document is an official announcement about a capital incentive plan involving share grants to employees and executives, which fits best under the category of Capital/Financing Update (CAP).
2024-12-16 Chinese
圣湘生物科技股份有限公司第二届董事会2024年第十次临时会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board meeting of 圣湘生物科技股份有限公司 (Shengxiang Bio-tech Co., Ltd.). It details the meeting date, attendance, and specific decisions made, including adjustments to a stock incentive plan and the appointment of a senior executive. The document does not contain financial statements or detailed financial data but rather announces management decisions and board resolutions. It also references other announcements for detailed information. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related board decisions.
2024-12-16 Chinese
圣湘生物科技股份有限公司监事会关于2023年第二期限制性股票激励计划预留授予激励对象名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on the verification of the reserved grant list of incentive targets under the company's 2023 second restricted stock incentive plan. It references relevant laws and regulations regarding stock incentive plans and confirms the eligibility of the incentive recipients. The document is a formal opinion or statement related to a stock incentive plan, not a full financial report, earnings release, or capital update. It does not contain financial statements or detailed financial data. It is not an announcement of voting results or a proxy solicitation. The content fits best under Regulatory Filings (RNS) as it is a compliance-related supervisory board opinion on stock incentive matters, which does not fit other more specific categories.
2024-12-16 Chinese
湖南启元律师事务所关于圣湘生物科技股份有限公司2023年第二期限制性股票激励计划授予价格调整及授予预留部分限制性股票的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the adjustment of the grant price and the reserved portion of restricted stock under a 2023 second phase restricted stock incentive plan of a company. It discusses compliance with relevant laws, regulations, approvals by the board, supervisory board, and shareholders, and confirms the legality and procedural correctness of the stock incentive plan adjustments and grants. The document is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to a capital incentive plan. It is not an announcement of voting results or a proxy solicitation, but a legal opinion supporting the stock incentive plan adjustments. This type of document fits best under the category of Regulatory Filings (RNS) as it is a legal compliance document that does not fit other specific categories such as Remuneration Information or Capital/Financing Update. The document length is over 6000 characters and contains substantive legal content, not just a brief announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2024-12-16 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.